Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TargetRANK

Financiado

Targeting RANK receptor as a novel therapeutic strategy in triple negative breas...

Targeting RANK receptor as a novel therapeutic strategy in triple negative breast cancer Breast cancer is the most common malignancy among females in the western world, resulting in nearly half a million deaths annually, mainly due to metastatic disease. Triple negative breast cancer (TNBC) accounts for almost 15–20%... ver más

31/08/2024

FUNDACION SECTOR P...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-31

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

FUNDACION SECTOR PUBLICO EST...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-112760RB-I00 DEFINIR EL MECANISMO DE ACTIVACION DE CDCP1 PARA BLOQUEAR ME... 182K€ Cerrado

CanceRusolution A NEW DRUG TO TREAT TRIPLE NEGATIVE BREAST CANCER 75K€ Cerrado

ATR2023-143492 Cáncer 992K€ Cerrado

PCIN-2015-128 HACIA UNA TERAPIA UNICA CONTAR EL CANCER DE MAMA TRIPLE NEGA... 48K€ Cerrado

PDC2021-121688-I00 INHIBIDORES DE LA DIMERIZACION DEL RECEPTOR DE ANDROGENOS CO... 144K€ Cerrado

SAF2017-86117-R NUEVOS AVANCES EN EL ESTUDIO DE LA VIA DE RANK EN CANCER DE... 230K€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2022-06-13
Fecha Fin: 2024-08-31

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Presupuesto del proyecto 150K€

Descripción del proyecto Breast cancer is the most common malignancy among females in the western world, resulting in nearly half a million deaths annually, mainly due to metastatic disease. Triple negative breast cancer (TNBC) accounts for almost 15–20% of all breast cancers (300.000 women diagnosed worldwide per year) and is commonly diagnosed in women younger than age 40. TNBC remains a clinical challenge due to high rate of relapse, a propensity to form visceral metastasis and limited targeted therapies. Thus, there is an urgent need to identify novel targeted therapies for the treatment of the TNBC. TargetRANK is based on the innovative idea of generating novel drugs targeting RANK receptor – instead of its ligand RANKL – for the treatment of TNBC, as well as a new panel of anti-RANK human antibodies – for research and diagnostic purposes. Small molecule inhibitors generated during the project could plausibly be positioned as a novel targeted therapy for TNBC and anti-RANK antibodies commercialized for research applications due to the lack of specific antibodies on the market. The most important benefits of TargetRANK are based on the unmet need to improve the treatment of TNBC patients, and the economic burden for public health systems generated by standard non-selected and ineffective cancer treatments. In addition, if drugs against RANK prove to be efficient, TargetRANK derived assets could also clinically benefit most of the patients suffering bone metastasis that are currently treated with bone resorption drugs, denosumab and bisphosphonates. Although our products are aimed for breast cancer, they may be therapeutically relevant for other tumors expressing RANK as non-small cell lung cancer. RANK antibodies will allow to stratify patients that might benefit from RANK blocking molecules, improving the existing treatments for skeletal-related events and reducing the main complications associated with life-altering morbidity affecting several types of prevalent cancers.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores